Abstract
In December 2020, the US Food and Drug Administration issued emergency use authorizations for two mRNA vaccines against coronavirus disease 2019. These vaccines represent an incredible scientific achievement and a major step in efforts to bring the global pandemic to a close. However, these vaccines create many logistical challenges that limit just how far-reaching their impact can be. This commentary reviews how these vaccines offer immunity, summarizes the Phase III trial results, and offers a discussion of the challenges that remain after these vaccines are introduced for widespread use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 549-556 |
| Number of pages | 8 |
| Journal | Clinical Therapeutics |
| Volume | 43 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
Funding
The author thanks Andi Shane, MD, MPH, for her thoughtful and detailed input on the content of this commentary, and Taylor Heald-Sargent, MD, PhD for her input on content of the figures. He offers his best wishes to health care worker colleagues who continue to work under challenging circumstances to provide care to those in need in this pandemic.
Keywords
- COVID-19
- SARS CoV-2
- Spike protein
- mRNA vaccines
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
